Psychiatry
M-A | Risk factors associated with post−COVID-19 condition
28 Mar, 2023 | 15:07h | UTCCommentary:
Meta-analysis reveals risk, protective factors for long COVID – CIDRAP
Long Covid: University of East Anglia study finds women more likely affected – BBC
M-A | Cognitive behavior therapy vs. other treatments for depression
28 Mar, 2023 | 15:05h | UTCCommentary: Is cognitive behavioural therapy the best we’ve got for depression? – The Mental Elf
Review | Navigating the new eating disorder landscape: atypical anorexia and avoidant/restrictive food intake disorder
24 Mar, 2023 | 13:03h | UTCPitfalls and Risks of “New Eating Disorders”: Let the Expert Speak! – Nutrients
Commentary: A review on two novel eating disorders – News Medical
RCT | Impact of sleep deprivation on health-related quality of life in healthy children
23 Mar, 2023 | 12:57h | UTCCommentaries:
Sleep Disruption Linked to Lower HRQOL in Children – HealthDay
How just 39 minutes of sleep can make or break your child’s health, happiness and school day – CNN
M-A | eHealth-based psychosocial interventions for adults with insomnia
23 Mar, 2023 | 12:31h | UTC
M-A | Comparison of mental health symptoms before and during the covid-19 pandemic
21 Mar, 2023 | 13:40h | UTCEditorial: Mental health and the covid-19 pandemic – The BMJ
News Release: Study suggests little deterioration in mental health linked to the pandemic – BMJ Newsroom
Commentaries:
A patient’s perspective on mental health and the pandemic – The BMJ
World’s most comprehensive study on COVID-19 mental health – McGill University
Guidelines for the management of patients with substance intoxication presenting to the ED
17 Mar, 2023 | 13:09h | UTC
RCT | Adjunctive Cariprazine for the treatment of patients with major depressive disorder
17 Mar, 2023 | 13:01h | UTCAdjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study – American Journal of Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
RCT: Adjunctive cariprazine (1.5 mg/d) demonstrated efficacy in reducing depressive symptoms in adults with MDD and inadequate response to ADs vs. placebo at week 6 (−14.1 vs. −11.5) https://t.co/k4QST25FeF
— P𝘧OL (@psychopharmacol) March 3, 2023
M-A | Prevalence of perinatal depression in low- and middle-income countries
17 Mar, 2023 | 12:49h | UTC
Commentary on Twitter
Depression amongst women, during pregnancy and up to a year postpartum, in low- and middle-income countries is common. Urgent action is required improve health outcomes for women and babies. https://t.co/xMSiqaOmiu @PerinatalEpi @mercyperinatal @UniMelb
— JAMA Psychiatry (@JAMAPsych) March 8, 2023
Cohort Study | Timing of antidepressant discontinuation during pregnancy and postpartum psychiatric outcomes
17 Mar, 2023 | 12:48h | UTC
Commentary on Twitter
A population-based study of 57,934 pregnant women in Denmark and Norway found that women who were previously stable antidepressant users but discontinued treatment late in pregnancy presented an elevated probability of postpartum initiating psycholeptics. https://t.co/k42OhXwgfi
— JAMA Psychiatry (@JAMAPsych) March 9, 2023
Cohort Study | Risk of interpersonal violence during and after pregnancy among people with schizophrenia
16 Mar, 2023 | 12:56h | UTCNews Release: Pregnant people with schizophrenia have threefold risk of interpersonal violence – Canadian Medical Association Journal
M-A | Comparison of pediatric emergency department visits for attempted suicide before and during the COVID-19 pandemic
15 Mar, 2023 | 14:56h | UTC
Scanxiety among adults with cancer: a scoping review to guide research and interventions
14 Mar, 2023 | 13:55h | UTCSummary: The article presents a scoping review of existing literature on scanxiety, which refers to the anxiety and distress experienced by cancer patients before and after medical imaging scans. The authors identified and synthesized findings from 36 articles on scanxiety among adults diagnosed with current or prior cancer.
The authors observed that scanxiety is a prevalent issue throughout the cancer continuum and may be linked to various factors related to the procedure itself or the uncertainty surrounding the possible outcomes of the scans.
The waiting period between the scan procedure and receipt of the results was described as particularly stressful, with participants reporting feeling overwhelmed by negative thoughts and fears about the potential outcomes of the scan. Some participants even found it difficult to focus on daily activities or responsibilities during this time.
The authors suggest that implementing supportive measures during scan experiences, including examining the waiting period between scans and scan results, could enhance the well-being for individuals with cancer who are going through different stages of treatment.
Article: Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions – Cancers
Adolescent substance use | Objective assessment with hair analysis nearly doubled the estimated prevalence based on self-reported data
14 Mar, 2023 | 13:34h | UTCNews Release: Hair analysis shows child drug use could be twice as high as we think – Taylor & Francis Group
Cohort Study | Depression and poor mental health linked to premature CVD and suboptimal CVH in young adults
10 Mar, 2023 | 14:14h | UTC
Commentary on Twitter
A new analysis of #BRFSS data from >600K young adults finds double the odds of #CVD in people with depression. #AHAJournals @GarimaVSharmaMD https://t.co/ZFzTTnUs95 pic.twitter.com/gvIAqbg47H
— JAHA (@JAHA_AHA) January 31, 2023
Perspective | Antipsychotics are increasingly being prescribed to children – here’s why we should be concerned
8 Mar, 2023 | 14:29h | UTCOriginal study: Cohort Study | Trends in antipsychotic prescribing to children and adolescents in England
RCT | Antipsychotic association seems better than antidepressant switch in treatment-resistant geriatric depression
6 Mar, 2023 | 14:23h | UTCSummary:
This open-label randomized trial compared the benefits and risks of augmenting therapy vs. switching antidepressants in older adults with treatment-resistant depression. In the first step, 619 patients were randomly assigned to augmentation of existing antidepressant medication with aripiprazole (an antipsychotic), augmentation with bupropion, or a switch from existing antidepressant medication to bupropion. In step 2, 248 patients who did not benefit from or were ineligible for step 1 were randomly assigned to augmentation with lithium or a switch to nortriptyline.
The aripiprazole-augmentation group showed significant improvement in well-being compared to the switch-to-bupropion group. Remission occurred in 28.9% of patients in the aripiprazole-augmentation group, 28.2% in the bupropion-augmentation group, and 19.3% in the switch-to-bupropion group. In step 2, similar remission rates occurred in the lithium-augmentation group (18.9%) and the switch-to-nortriptyline group (21.5%).
Article: Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
#AAGPAM23: In a pragmatic trial involving older persons with treatment-resistant depression, augmentation of existing antidepressants with aripiprazole was better than augmentation with bupropion or a switch to bupropion. Full results of the OPTIMUM trial: https://t.co/2OPOxH67Qx pic.twitter.com/g0AtrYGhKV
— NEJM (@NEJM) March 3, 2023
Perspective | Why functional neurological disorder is not feigning or malingering
6 Mar, 2023 | 14:17h | UTCWhy functional neurological disorder is not feigning or malingering – Nature Reviews Neurology (free for a limited period)
Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews
3 Mar, 2023 | 14:11h | UTCSummary: This umbrella review summarized the evidence on the effects of physical activity interventions on symptoms of depression, anxiety, and psychological distress in adult populations. The study included 97 systematic reviews comprising 1039 randomized controlled trials and 128,119 participants. The results showed that physical activity had medium effects on depression, anxiety, and psychological distress compared to usual care across all populations. Higher-intensity physical activity was associated with greater improvements in symptoms, and the effectiveness of physical activity interventions diminished with longer-duration interventions. The authors concluded that physical activity is highly beneficial for improving symptoms of depression, anxiety, and distress in a wide range of adult populations, including those with mental health disorders and chronic diseases, and should be a mainstay approach in their management.
Article: Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews – British Journal of Sports Medicine (link to abstract – $ for full-text)
News Release: Exercise more effective than medicines to manage mental health – University of South Australia
Commentary from the authors: Exercise is even more effective than counselling or medication for depression. But how much do you need? – The Conversation
Commentary on Twitter
📣 Effectiveness of #PhysicalActivity for improving depression, anxiety and distress: an overview of #SystematicReviews 🔎📄#KeyPoints:
🧠Higher intensity = greater improvements 🏋️♂️
🧠 Effect diminished with longer duration interventions 📉👉 https://t.co/UJRRFVz7eG pic.twitter.com/5JT9xEVMsa
— British Journal of Sports Medicine (BJSM) (@BJSM_BMJ) February 19, 2023
RCT | Reducing social media use improves appearance and weight esteem in youth with emotional distress
3 Mar, 2023 | 14:04h | UTCSummary: The article discusses a randomized controlled trial conducted on 220 participants aged 17-25 to examine the effects of reducing smartphone social media use (SMU) on appearance and weight esteem in youth with emotional distress. The participants were divided into an intervention group (limited to 1 hr/day SMU) and a control group (unrestricted SMU). The study found that reducing SMU improved appearance and weight esteem in the intervention group, while the control group showed no significant change. The authors concluded that reducing SMU may be a feasible and effective method of improving body image in a vulnerable youth population and should be evaluated as a potential component in treating body image-related disturbances. It is worth noting, however, that the impossibility of blinding participants and the subjective nature of the endpoints make it difficult to draw definitive conclusions on the subject.
News Release: Reducing social media use significantly improves body image in teens, young adults – American Psychological Association
Commentary: How to help young people limit screen time — and feel better about how they look – NPR
M-A | Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata
2 Mar, 2023 | 12:59h | UTCPrevalence and Odds of Depressive and Anxiety Disorders and Symptoms in Children and Adults With Alopecia Areata: A Systematic Review and Meta-analysis – JAMA Dermatology (link to abstract – $ for full-text)
Commentary: Anxiety, Depressive Disorder Prevalence Greater Among Alopecia Areata Patients – HCP Live
RCT | Electrostimulation with the Alpha-Stim AID device is not better than sham treatment in major depression
2 Mar, 2023 | 12:49h | UTCCommentary: Active AID Device Not More Effective Than Sham at Improving Depressive Symptoms – Neurology Advisor
Review | Borderline personality disorder
1 Mar, 2023 | 14:04h | UTCBorderline Personality Disorder: A Review – JAMA (free for a limited period)
JAMA Patient Page: Borderline Personality Disorder
M-A | Efficacy of brief behavioral therapy for insomnia in older adults with chronic insomnia
1 Mar, 2023 | 13:55h | UTC
RCT | Efficacy of oral vs. long-acting antipsychotic treatment in patients with early-phase schizophrenia
1 Mar, 2023 | 13:38h | UTCEfficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST) – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary: No benefit of long-acting antipsychotics in schizophrenia? – MDedge


